Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications

This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging...
Ausführliche Beschreibung

This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. Ausführliche Beschreibung